Plain-English translation of NCT07156201 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human study testing a new medication called to see if it is safe and how the body processes it. The trial will enroll healthy volunteers who will receive either the medication or a placebo (a dummy pill with no active ingredient), and researchers will carefully monitor how participants respond.
This medication is being developed to treat KCNT1-related epilepsy, a rare and serious form of seizure disorder. Before this treatment can be tested in patients with the condition, researchers need to confirm that it is safe and understand how the body absorbs and uses it.
You likely qualify if…
You likely don't qualify if…
Participants will go through three separate studies. In the first, you'll receive a single dose of the medication or placebo and be monitored for two weeks. In the second, you'll take daily doses for 14 days and then be followed for two more weeks. In the third, you'll take doses under different conditions (with and without food, and with another medication) to see how these factors affect the treatment. All participants will have screening visits beforehand and follow-up visits to check your health and blood work.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Australia